Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 9;14(11):100604.
doi: 10.1016/j.waojou.2021.100604. eCollection 2021 Nov.

The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019

Wen-Lan Dong  1 , Jing An  2 , Miao Yu  3 , Peng Yin  1 , Ting-Ling Xu  1 , Bo Liu  3 , Torsten Zuberbier  4 , Zuo-Tao Zhao  3 , Mai-Geng Zhou  1
Affiliations

The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019

Wen-Lan Dong et al. World Allergy Organ J. .

Abstract

Background: Atopic dermatitis (AD) is a chronic disease with growing prevalence and has become a global public health problem. However, little is known about the burden caused by AD in China.

Objective: To access the prevalence and burden of AD in China.

Methods: We estimated the prevalence and year lived with disability (YLD) of AD in China, by different age and sex groups. We also compared the burden of AD in China with other countries in the Group of Twenty (G20). We analyzed the changes in the number of AD patients and their YLDs by cause decomposition from 1990 to 2019.

Results: AD was the twenty-fourth leading cause of the burden of 369 diseases in China in 2019. From 1990 to 2019, the age-standardized prevalence and YLD rate of AD in China increased by 1.04% and 1.43% respectively, which were the second and the largest increase among the G20 and both higher than the global average (-4.29% and -4.14%). The number of patients with AD increased by 25.65%, of which 20.16% was due to population growth, 3.85% due to population aging, and 1.64% due to age-specific prevalence. Both the prevalence and YLD rate of AD were higher in 1 to 4 year-olds and 95+ years age group. Before the age of 10, the prevalence and YLD rate of AD in males were higher than those in females, while there was a marked sex shift at the ages of 10 to 14.

Conclusion: AD is a serious public health problem in China. Substantial variations exist in burden due to AD between male and female, and in age groups. Considering these findings will be important for developing preventive strategies and treatments to reduce the burden of AD.

Keywords: Atopic dermatitis; Burden; GBD 2019; Prevalence; Years lived with disability.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A. The atopic dermatitis prevalence rate of male and female of different ages in China in 1990. B. The atopic dermatitis prevalence rate of male and female of different ages in China in 2019
Fig. 2
Fig. 2
A. The atopic dermatitis YLD rate of male and female of different ages in China in 1990. B. The atopic dermatitis YLD rate of male and female of different ages in China in 2019. YLD: years lived with disability
See this image and copyright information in PMC

References

    1. Fuiano N., Delvecchio M., Incorvaia C. Factors associated with different results of allergy tests in children with dust mite-induced atopic dermatitis. Allergol Immunopathol. 2015;43(3):238–242. doi: 10.1016/j.aller.2014.02.008. - DOI - PubMed
    1. Silverberg J.I., Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol. 2015;135(3):721–728.e6. doi: 10.1016/j.jaci.2014.11.023. - DOI - PubMed
    1. Andersen Y.M.F., Egeberg A., Gislason G.H., Hansen P.R., Skov L., Thyssen J.P. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):310–312.e3. doi: 10.1016/j.jaci.2016.01.015. - DOI - PubMed
    1. GBD Results Tool. Available at: https://collab2019.healthdata.org/gbd-search. Accessed November 20, 2020.
    1. Global Health Data Exchange. Available at: http://ghdx.healthdata.org, Accessed November 20, 2020.

LinkOut - more resources